A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...

Some vaccines may reduce the risk of dementia through a double effect in which the jabs help protect the brain through their ...

Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

GSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted the company's regulatory ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

AREXVY is not approved for use in persons <50 years of age Vaccination with AREXVY may not result in protection of all vaccine recipients Please see full Prescribing Information for AREXVY.

Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...

PHILADELPHIA, April 16, 2025--AREXVY recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices ...

Abrysvo or Arexvy Market Regional and Country Analysis 10.1. Global Abrysvo or Arexvy Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million 10.2.

AREXVY is not approved for use in persons <50 years of age Vaccination with AREXVY may not result in protection of all vaccine recipients Please see full Prescribing Information for AREXVY.